Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

AbbVie seeks FDA approval for a groundbreaking oral treatment combining venetoclax and acalabrutinib, promising a new era in ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma Sep. 29, 2023 7:15 AM ET AbbVie Inc. (ABBV) ...

* ABBVIE INC - IN CLL14 TRIAL, ADVERSE EVENTS WERE CONSISTENT WITH KNOWN SAFETY PROFILES OF VENETOCLAX AND OBINUTUZUMAB ALONE Source text for Eikon: Further company coverage: ...

In the first three months of 2025, the drug added sales worth $665 million to AbbVie’s top line, up 12% year over year. This growth is being driven by strong demand for both CLL and AML indications.

NORTH CHICAGO, Ill., June 9, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new findings demonstrating sustained long-term safety and efficacy of VENCLYXTO ® / VENCLEXTA ® (venetoclax ...

* ABBVIE INC - PARTIAL CLINICAL HOLD FOLLOWS A REVIEW OF DATA FROM ONGOING PHASE 3 BELLINI TRIAL (M14-031) * ABBVIE INC - TUESDAY'S ACTION DOES NOT IMPACT ANY OF APPROVED INDICATIONS FOR VENETOCLAX ...

AbbVie is conducting an observational study titled ‘Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany ...

It seems venetoclax could be a new option for this large but difficult-to-treat population. In a phase 2 study with 107 patients who had failed a median of two prior therapies, a surprising 85 ...